Akari Therapeutics PLC Email Format

BiotechnologyNew York, United States11-50 Employees

Akari Therapeutics PLC is a clinical-stage biotechnology company based in New York, focused on developing therapies for orphan autoimmune and inflammatory diseases. Its lead candidate, Coversin, is a recombinant protein that inhibits complement component C5, blocking the release of C5a and the formation of the membrane attack complex. Derived from a parasite protein found in the saliva of the Ornithodoros moubata tick, the molecule represents a targeted approach to modulating the immune response in these conditions. In 2026, Akari expanded its research scope toward oncology by developing antibody-drug conjugates with novel payloads and forming a collaboration with WuXi XDC to develop and manufacture these ADC treatments. The company’s activities are anchored in the biotechnology research industry, with a relatively small team based in New York.

Get verified Akari Therapeutics PLC emails free

Company overview Employee directory